Hoffmann-la Roche Inc.

Roche Glycart Ag

Engmab Sarl

Other

Bristol-myers Squibb Compnay

Glycart Biotechnology Ag

Roche Glyeart Ag

Engmab Ag

F. Hoffmann-la Roche Ag

Engmab Beta Holdings LLC

Orano Med Manufacturing Sas

Pablo Umana

Christian Klein

Ekkehard Moessner

Ralf Hosse

Peter Bruenker

Marina Bacac

Thomas U Hofer

Oliver Ast

Anne Freimoser-Grundschober

Joerg Thomas Regula

Claudia Ferrara Koller

Sandra Grau-Richards

Valeria G Nicolini

Christina Claus

Viktor Levitski

Maria Amann

Christiane Neumann

Wolfgang Schaefer

Stefan Seeber

Michael Molhoj

Stefan Klostermann

Juergen Michael Schanzer

Guy Georges

Sabine Imhof-Jung

Jens Fischer

Harald Duerr

Ulrich Brinkmann

Claudio Sustmann

Erhard Kopetzki

Kay-Gunnar Stubenrauch

Georg Fertig

Tilman Schlothauer

Stefan Dengl

Joerg Moelleken

Werner Scheuer

Peter Sondermann

Huisheng Wang

Thomas Emrich

Valeria Lifke

Lei Shi

Peng Wang

Andrew G Polson

Olaf Mundigl

Petra Rueger

Jigar Patel

James E Bailey

Hendrik Knoetgen

Ekkehard Mössner

Eike Hoffmann

Frank Herting

Thomas Friess

Laurent Lariviere

Uwe Wessels

Johannes Auer

Samuel Moser

Tanja Fauti

Inja Waldhauer

Tina Weinzierl

Klaus Strein

Minh Diem Vu

Sylvia Herter

Lydia Jasmin Hanisch

Alexander Bujotzek

Kathryn Elizabeth Packman

Wei Xu

Rebecca Croasdale

Julien Torgue

Johannes Sam

Laura Codarri Deak

Joerg Zielonka

Christian Gerdes

Rebecca Croasdale-Wood

Changhua Ji

Laurence Bernard Peterson

Linda Wicker

Christiane Jaeger

Maximiliane Koenig

Barbara Weiser

Tobias Suter

Valeria Runza

Katharina Wartha

Mario Perro

Adrian Zwick

Alfred Zippelius

Huifeng Niu

Laura Codarri-Deak

Moritz Rapp

Christine Trumpfheller

Ildiko Wuensche

Stefan Evers

Jose Saro

Sherif Daouti

Ningping Feng

Hans Koll

Roland Staack

Jan Olaf Stracke

Eric Sullivan

Wilma Lau

Silke Metz

Martina Geiger

The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.

Methods of treating cancer by administering tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding molecules

The invention provides antibodies against Fibroblast Activation Protein (FAP) and methods of using the same.

Anti-FAP antibodies and methods of use

The present invention relates to combination therapies employing 4-1BB (CD137) agonists, in particular 4-1BBL trimer containing antigen binding molecules, in combination with HER-2 targeting agents, the use of these combination therapies for the treatment of cancer, and methods of using the combination therapies.

Combination therapy with targeted 4-1BB (CD137) agonists

The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP) comprising FAP clone 212 or variants thereof, and (b) at least one antigen binding domain capable of specific binding to CD40, and to methods of producing these molecules and to methods of using the same.

Bispecific antigen binding molecules comprising anti-FAP clone 212

The invention relates autonomous VH domains (aVH) with cysteines in positions 52a and 71 or in positions 33 and 52 in order to stabilize the autonomous VH domains. Said cysteines are capable of forming a disulfide bond and/or form a disulfide bond under suitable conditions. The invention further relates to aVH libraries.

Stabilized immunoglobulin domains

The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one moiety capable of specific binding to a target cell antigen, (b) at least one moiety capable of specific binding to a costimulatory TNF receptor family member, and (c) a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.

Bispecific antibodies specific for OX40

The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen, (b) a polypeptide comprising three ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by peptide linkers and (c) a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.

Antigen binding molecules comprising a trimeric TNF family ligand and encoding polynucleotides thereof

The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target 511cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

T cell activating bispecific antigen binding molecules

The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells comprising a common light chain. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

The invention relates to Her2 targeting 4-1BB agonists, in particular 4-1BBL trimer-containing antigen binding molecules comprising at least one antigen binding domain capable of specific binding to Her2 and their use in the treatment of cancer as well as their use in combination with T-cell activating anti-CD3 bispecific antibodies.

HER2-targeting antigen binding molecules comprising 4-1BBL

The present invention generally relates to immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-2 polypeptide and an antibody that binds to PD-1. In addition, the invention relates to polynucleotide molecules encoding the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.

Immunoconjugates

The present invention relates to bispecific antibodies against ROR1 and CD3, their manufacture and use.

Bispecific antibodies against CD3EPSILON and ROR1

The present invention relates to the combination therapy of specific PD-1-targeted IL-2 variant immunocytokines with specific antibodies which bind human PD-L1.

Combination therapy of PD-1-targeted IL-2 variant immunocytokines and antibodies against human PD-L1

The present invention generally relates to antibodies that bind to NKG2D, including multispecific antigen binding molecules e.g. for activation of T cells and/or NK cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Antibodies binding to NKG2D

The present invention relates to bispecific HER2 antibodies, novel HER2 antibody variants, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Bispecific HER2 antibodies and methods of use

Growing community of inventors

Wollerau, Switzerland

Pablo Umana